anonymous
Guest
anonymous
Guest
You sound like a coward. Go try to help some pt's. Otherwise shut the up.
Management drunk posting again?
You sound like a coward. Go try to help some pt's. Otherwise shut the up.
Should I wait for the package or take I offer I got today? Or take the offer and work both until Shire gives everyone a package? Decisions, decisions ...
More layoffs this quarter?
Q: You know what Shire calls reps who don’t perform don’t ya?
A: Regional Business Directors
480,000 IDIOTS! Move on or know your drug!Increase in revenue due to continuing price increases. $300,000/year at launch and now well over $400,000/year without any data other than the original Phase 3 study.
My RBD told our entire team to start looking. From what I hear not all RBD’s are being as honest about things as mine
Mine says we will be fine! There is no way they are touching the Gattex team as it’s so complicated of a sale and the leadership team has been pushing for Takeda to leave us alone. .
You sample droppers are oh so gullible. Keep drinking the kool-aid that they are serving up. Takeda will do whatever Takeda wants. This includes dismantling FO’s failed attempt at building his rare disease empire. Takeda is getting out of the rare disease business one asset at a time. The writing is on the wall for the Gattex team.
Like Takeda even cares what our management tells them to do with Gattex. Takeda is going to 86 it out of their product portfolio on 1/8.
If we are lucky they will. Who the hell wants to work at Takeda?
Gattex will be put on the shelf somewhere. It is pointless to have over 100 people selling a brand that is doing 150mm a year. Oh and guess what it was when Shire bought it....135mm a year....so basically without the price increases the drug has lost revenue.
Through the first three quarters of 2018, Gattex has sold $327 million in NET sales - read the quarterly presentations. That puts it on track to do well above $400 million in 2018. Honestly, people, to say sales haven't grown is crazy.